Your browser is no longer supported. Please, upgrade your browser.
Settings
CRSP [NASD]
CRISPR Therapeutics AG
Index- P/E- EPS (ttm)-3.25 Insider Own1.20% Shs Outstand70.14M Perf Week-13.61%
Market Cap11.90B Forward P/E- EPS next Y-5.31 Insider Trans-41.97% Shs Float64.11M Perf Month-2.70%
Income-211.30M PEG- EPS next Q-1.27 Inst Own75.60% Short Float6.04% Perf Quarter74.17%
Sales77.40M P/S153.76 EPS this Y134.10% Inst Trans15.14% Short Ratio2.18 Perf Half Y89.76%
Book/sh19.15 P/B8.56 EPS next Y-5.80% ROA-18.40% Target Price146.56 Perf Year196.26%
Cash/sh18.82 P/C8.71 EPS next 5Y- ROE-20.70% 52W Range32.30 - 220.20 Perf YTD7.08%
Dividend- P/FCF- EPS past 5Y54.00% ROI4.90% 52W High-25.54% Beta2.38
Dividend %- Quick Ratio16.50 Sales past 5Y- Gross Margin- 52W Low407.59% ATR13.98
Employees304 Current Ratio16.50 Sales Q/Q-100.00% Oper. Margin- RSI (14)44.28 Volatility7.59% 8.27%
OptionableYes Debt/Eq0.00 EPS Q/Q-154.80% Profit Margin- Rel Volume1.95 Prev Close169.53
ShortableYes LT Debt/Eq0.00 EarningsOct 28 BMO Payout- Avg Volume1.78M Price163.95
Recom2.40 SMA20-9.11% SMA507.15% SMA20067.29% Volume3,467,481 Change-3.29%
Dec-10-20Reiterated Needham Buy $105 → $170
Dec-10-20Reiterated Chardan Capital Markets Buy $110 → $166
Dec-10-20Downgrade Jefferies Buy → Hold
Dec-07-20Downgrade Wells Fargo Overweight → Equal Weight $145
Oct-23-20Initiated RBC Capital Mkts Sector Perform $110
Oct-05-20Initiated BofA Securities Buy $110
Jul-28-20Reiterated Needham Buy $84 → $105
Jul-14-20Initiated SunTrust Buy $140
Jun-15-20Reiterated Canaccord Genuity Buy $80 → $84
Mar-05-20Initiated Stifel Hold $52
Feb-03-20Downgrade Evercore ISI Outperform → In-line $85 → $52
Nov-19-19Upgrade William Blair Mkt Perform → Outperform
Nov-12-19Upgrade Oppenheimer Perform → Outperform $65
Aug-01-19Initiated Jefferies Buy $64
Jul-26-19Initiated Canaccord Genuity Buy $72
Jun-10-19Initiated ROTH Capital Buy $50
Apr-12-19Initiated Evercore ISI Outperform
Mar-14-19Initiated William Blair Mkt Perform
Jan-28-19Downgrade Goldman Buy → Neutral
Jan-22-19Downgrade Citigroup Neutral → Sell
Jan-21-21 02:43PM  
Jan-20-21 08:23AM  
Jan-19-21 10:46AM  
Jan-18-21 08:41AM  
Jan-15-21 06:12PM  
Jan-14-21 03:11PM  
01:22PM  
Jan-12-21 01:24PM  
Jan-11-21 08:02AM  
Jan-08-21 09:01AM  
Jan-07-21 04:24PM  
10:38AM  
08:42AM  
Jan-06-21 02:25PM  
11:00AM  
Jan-01-21 02:42PM  
Dec-29-20 12:27PM  
Dec-23-20 07:29PM  
Dec-22-20 03:00PM  
10:01AM  
09:48AM  
Dec-21-20 04:24PM  
12:12PM  
08:43AM  
Dec-16-20 05:17AM  
Dec-15-20 07:03AM  
Dec-14-20 08:00AM  
Dec-13-20 06:45AM  
02:04AM  
Dec-12-20 03:39PM  
Dec-10-20 02:03PM  
01:45PM  
12:47PM  
Dec-09-20 01:10PM  
11:27AM  
Dec-08-20 04:45PM  
08:44AM  
Dec-07-20 04:20PM  
09:19AM  
Dec-05-20 12:30PM  
Dec-01-20 09:00AM  
Nov-24-20 08:00AM  
Nov-21-20 06:33AM  
Nov-20-20 09:17AM  
Nov-16-20 08:00AM  
Nov-14-20 05:24AM  
Nov-07-20 07:04AM  
Nov-04-20 04:17PM  
03:16PM  
02:11PM  
09:15AM  
Nov-02-20 07:34AM  
Oct-31-20 06:43AM  
Oct-29-20 08:51AM  
Oct-28-20 04:59PM  
08:00AM  
Oct-24-20 08:55AM  
Oct-22-20 05:41PM  
01:11PM  
11:22AM  
Oct-21-20 05:58PM  
04:26PM  
12:19PM  
10:02AM  
08:04AM  
07:00AM  
Oct-16-20 12:12PM  
Oct-15-20 11:18AM  
Oct-12-20 09:45AM  
Oct-09-20 10:14AM  
Oct-08-20 01:31PM  
Oct-07-20 06:05PM  
10:04AM  
09:26AM  
Oct-05-20 02:23PM  
12:28PM  
Sep-30-20 06:45AM  
Sep-29-20 08:00AM  
Sep-24-20 06:04AM  
Sep-23-20 11:03AM  
Sep-22-20 09:00AM  
Sep-15-20 11:00AM  
Sep-14-20 07:20AM  
Sep-10-20 06:55AM  
Sep-09-20 05:26PM  
07:04AM  
Sep-03-20 08:00AM  
Aug-26-20 11:30AM  
Aug-20-20 08:33AM  
Aug-18-20 11:41AM  
Jul-30-20 08:00AM  
Jul-29-20 06:53AM  
Jul-28-20 03:53AM  
Jul-27-20 06:15PM  
05:01PM  
04:30PM  
12:31PM  
10:18AM  
Jul-26-20 08:10AM  
Jul-25-20 11:52AM  
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. It develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, the company is developing allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. Further, it engages in developing regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KASINGER JAMES R.General Counsel and SecretaryJan 19Option Exercise51.4927,5001,415,97549,931Jan 20 06:05 PM
KASINGER JAMES R.General Counsel and SecretaryJan 19Sale204.9427,5005,635,94422,431Jan 20 06:05 PM
Klein Lawrence OttoCBO & COOJan 15Option Exercise13.7925,010344,77636,334Jan 20 06:07 PM
Kulkarni SamarthChief Executive OfficerJan 15Option Exercise1.8120,00036,200202,989Jan 20 06:11 PM
Klein Lawrence OttoCBO & COOJan 15Sale215.2025,0005,379,94020,000Jan 20 06:07 PM
Kulkarni SamarthChief Executive OfficerJan 15Sale213.6720,0004,273,311182,989Jan 20 06:11 PM
Kulkarni SamarthChief Executive OfficerDec 29Option Exercise1.8113,80024,978182,989Dec 30 04:02 PM
Ho Tony WExecutive VP, Head of R&DDec 21Option Exercise16.9023,551398,01257,515Dec 22 04:55 PM
Ho Tony WExecutive VP, Head of R&DDec 21Sale149.2323,5513,514,61033,964Dec 22 04:55 PM
Bolzon Bradley J PhDDirectorDec 16Sale148.957,3521,095,089339,834Dec 18 07:12 PM
Bolzon Bradley J PhDDirectorDec 16Sale148.957,6481,139,1770Dec 18 07:12 PM
Kulkarni SamarthChief Executive OfficerDec 10Option Exercise1.8120,00036,200189,189Dec 11 04:05 PM
Kulkarni SamarthChief Executive OfficerDec 10Sale142.2920,0002,845,782169,189Dec 11 04:05 PM
Bolzon Bradley J PhDDirectorDec 10Sale143.3533,0004,730,448314,186Dec 14 07:11 PM
KASINGER JAMES R.General Counsel and SecretaryDec 09Option Exercise13.6222,026299,99422,415Dec 10 04:35 PM
Bolzon Bradley J PhDDirectorDec 07Sale154.53171,00426,424,505347,186Dec 09 07:54 PM
Novak RodgerPresidentNov 30Option Exercise14.22100,0001,421,500698,007Dec 02 04:26 PM
Novak RodgerPresidentNov 30Sale125.00100,00012,500,000648,007Dec 02 04:26 PM
Novak RodgerPresidentOct 09Option Exercise14.432,76239,856650,769Oct 13 04:44 PM
Novak RodgerPresidentOct 09Sale100.002,762276,200648,007Oct 13 04:44 PM
Novak RodgerPresidentOct 08Option Exercise14.4322,238320,894670,245Oct 13 04:44 PM
Novak RodgerPresidentOct 08Sale100.0022,2382,223,800648,007Oct 13 04:44 PM
Bolzon Bradley J PhDDirectorSep 18Sale86.873,035263,636518,190Sep 22 08:10 PM
Bolzon Bradley J PhDDirectorSep 16Sale86.988,965779,777521,225Sep 18 04:30 PM
Bolzon Bradley J PhDDirectorSep 14Sale84.891,15598,045530,190Sep 16 08:00 PM
Bolzon Bradley J PhDDirectorSep 10Sale85.3622,8451,949,996531,345Sep 11 09:49 PM
Bolzon Bradley J PhDDirectorSep 01Option Exercise25.2360,0001,513,95060,000Sep 03 09:21 PM
Novak RodgerPresidentSep 01Option Exercise14.3625,000359,059673,007Sep 03 04:44 PM
TOMSICEK MICHAEL JOHNChief Financial OfficerSep 01Option Exercise17.7512,000213,00012,410Sep 03 04:46 PM
Novak RodgerPresidentSep 01Sale92.6225,0002,315,578648,007Sep 03 04:44 PM
TOMSICEK MICHAEL JOHNChief Financial OfficerSep 01Sale92.2612,0001,107,068410Sep 03 04:46 PM
Bolzon Bradley J PhDDirectorSep 01Sale92.5160,0005,550,6440Sep 03 09:21 PM
Novak RodgerPresidentAug 19Option Exercise14.0025,000350,000673,007Aug 21 04:11 PM
Novak RodgerPresidentAug 19Sale100.0025,0002,500,000648,007Aug 21 04:11 PM
TOMSICEK MICHAEL JOHNChief Financial OfficerAug 03Option Exercise17.7512,000213,00012,410Aug 05 04:20 PM
TOMSICEK MICHAEL JOHNChief Financial OfficerAug 03Sale86.7412,0001,040,919410Aug 05 04:20 PM
Novak RodgerPresidentJul 07Option Exercise11.2825,000281,907673,007Jul 09 04:00 PM
Novak RodgerPresidentJul 07Sale90.0025,0002,250,000648,007Jul 09 04:00 PM
Bolzon Bradley J PhDDirectorJul 06Sale82.3920,0001,647,730554,190Jul 08 04:00 PM
Novak RodgerPresidentJul 01Sale80.0050,0004,000,000648,007Jul 06 04:14 PM
Klein Lawrence OttoCBO & COOJun 25Option Exercise12.574,91261,74424,912Jun 26 04:33 PM
Klein Lawrence OttoCBO & COOJun 25Sale75.184,912369,27220,000Jun 26 04:33 PM
Klein Lawrence OttoCBO & COOJun 24Option Exercise8.5865,088558,70758,666Jun 26 04:33 PM
Klein Lawrence OttoCBO & COOJun 24Sale75.9365,0884,942,29220,000Jun 26 04:33 PM
Novak RodgerPresidentJun 23Sale75.0050,0003,750,000698,007Jun 25 04:28 PM
Bolzon Bradley J PhDDirectorJun 23Sale75.3510,000753,453574,190Jun 24 07:02 PM
Ho Tony WExecutive VP, Head of R&DJun 23Sale75.206,929521,06133,747Jun 24 05:58 PM
Ho Tony WExecutive VP, Head of R&DJun 22Sale70.1422916,06240,676Jun 24 05:58 PM
Bolzon Bradley J PhDDirectorJun 22Sale72.5110,000725,069584,190Jun 24 07:02 PM
Kulkarni SamarthChief Executive OfficerJun 01Option Exercise1.8117,27531,268188,801Jun 03 05:32 PM
Kulkarni SamarthChief Executive OfficerJun 01Sale64.6817,2751,117,266171,526Jun 03 05:32 PM
Ho Tony WExecutive VP, Head of R&DMay 26Sale70.146,100427,85440,905May 27 04:32 PM
Novak RodgerPresidentMay 26Sale70.2736,6162,573,006748,007May 27 04:34 PM
Novak RodgerPresidentMay 22Sale70.0113,384937,014784,623May 27 04:34 PM
Ho Tony WExecutive VP, Head of R&DMay 22Sale70.0560042,03047,005May 27 04:32 PM
Kulkarni SamarthChief Executive OfficerMay 20Option Exercise1.8110,69319,354182,219May 21 04:35 PM
Kulkarni SamarthChief Executive OfficerMay 20Sale65.2810,693698,039171,526May 21 04:35 PM
Kulkarni SamarthChief Executive OfficerMay 19Option Exercise1.814,3077,796175,833May 21 04:35 PM
Novak RodgerPresidentMay 19Sale65.0050,0003,250,000798,007May 21 04:37 PM
Kulkarni SamarthChief Executive OfficerMay 19Sale65.164,307280,644171,526May 21 04:35 PM
Klein Lawrence OttoCBO & COOMay 11Option Exercise5.8625,000146,50045,000May 13 04:38 PM
Klein Lawrence OttoCBO & COOMay 11Sale60.4025,0001,509,97120,000May 13 04:38 PM